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Pharmacogenetic testing for clinical applications is steadily increasing. Correct and ade-
quate use of pharmacogenetic tests is important to reduce unnecessary medical costs 
and adverse patient outcomes. This document contains recommended pharmacogenetic 
testing guidelines for clinical application, interpretation, and result reporting through a lit-
erature review and evidence-based expert opinions for the clinical pharmacogenetic test-
ing covered by public medical insurance in Korea. This document aims to improve the 
utility of pharmacogenetic testing in routine clinical settings. 
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SCOPE AND PURPOSE 
Pharmacogenetics is a rapidly developing field, and the number 
of pharmacogenetics tests that can be utilized in clinical prac-
tice is also increasing. However, the clinical utility of such tests 
may differ depending on each patient’s specific situation and 
the interpretation of the pharmacogenetic test results. The pur-
pose of these guidelines is to introduce pharmacogenetic tests 
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that can be used in clinical practice and to examine the test ap-
plication criteria, result interpretation, and reporting methods 
based on the current literature to enhance the clinical utility of 
pharmacogenetic tests. We aim to publish the summarized Eng-
lish version here to present its essentials for more readers to un-
derstand, although the original version of this article has been 
published on Laboratory Medicine Online [1, 2]. The pharma-
cogenetic tests discussed in this guideline are limited to clinical 
tests covered by the Korea health insurance medical care ex-
penses for patient treatment. Pharmacogenetic tests for the pur-
pose of drug development or research have been excluded. 
METHOD OF RECOMMENDATION 
DEVELOPMENT 
These guidelines were developed according to the methodology 
of the Adaptation Process for Developing Korean Clinical Prac-
tice Guidelines Ver. 2.0 [3]. The adapted recommendation was 
agreed on by the committee and was based on the draft guide-
lines prepared by integrating selected existing guidelines and lit-
erature. The adopted recommendation was peer-reviewed by 
the development/writing/review committee. It was developed by 
the Pharmacogenetic Test Clinical Practice Guideline Develop-
ment Committee at the Korean Society of Laboratory Medicine 
(KSLM), the Korean Society of Clinical Chemistry, the Korean 
Association of Quality Assurance for Clinical Laboratories, and 
the Korean Institute of Genetic Testing Evaluation. This recom-
mendation was developed with the support of KSLM, but the 
Clinical Practice Guideline Committee worked independently 
during development/writing/review processes, and KSLM did 
not influence the development of the recommendation.
To develop the current guideline, the international guidelines 
related to pharmacogenetic tests for drugs and genes were sear-
ched. Among the guidelines published in the past five years, only 
the guidelines in English were selected, and those written by an 
individual who did not represent an organization were excluded. 
In situations where there was no guideline, systematic reviews 
were the primary targets of the search. Specific searching meth-
ods according to the genes are summarized on the clinical phar-
macogenetics testing and application: laboratory medicine clini-
cal practice guideline [4]. The comprehensive literature search 
examined databases such as MEDLINE, PubMed, Cochrane 
Database of Systematic Reviews, EMBASE, and KoreaMed, where 
the keywords for the search were the corresponding gene and 
target drug. Articles with human subjects published in English 
or Korean were searched, along with additional documentation, 
such as textbooks, recent publications, theses, and consulta-
tions from experts in the corresponding area. After removing 
duplicate documents, abstracts were reviewed to select docu-
mentation, and the actual text was reviewed to select the final 
target documentation.
These guidelines should be amended in three to five years fol-
lowing the development of new pharmacogenetic testing tech-
nologies, changes in the medical environment, and the accumu-
lation of evidence related to pharmacogenetic tests.
GUIDELINES PER GENE
This document contains recommendations for each gene and 
the rationale. The detailed information refers to LMO 2016 [1, 2].
The recommendations for CYP2C9 & VKORC1, CYP2C19, 
CYP2D6, and TPMT genotype tests have been prepared based 
on the Clinical Pharmacogenetics Implementation Consortium 
(CPIC) guideline under the National Institutes of Health’s Phar-
macogenomics Research Network (NIH PGRN) (CYP2C9 & 
VKORC1 [5], CYP2C19 [6, 7], CYP2D6 [8-10], TPMT [11, 12]), 
the Dutch Pharmacogenetics Working Group (DPWG) guideline 
[13], and the Laboratory Analysis and Application of Pharmaco-
genetics to Clinical Practice of the National Academy of Clinical 
Biochemistry (NACB) [14]. Recommendations for UGT1A1 gen-
otype tests were prepared on the basis of NACB’s Laboratory 
Analysis and Application of Pharmacogenetics to Clinical Prac-
tice [14], CPIC [15], and the DPWG guideline [13]. Recommen-
dations for NAT2 genotype tests were prepared on the basis of 
systematic review [16] because there was no representative gui-
deline for NAT2.
The recommendations based on EGFR genotype tests were 
prepared on the basis of the Molecular Testing Guideline of the 
College of American Pathologists/International Association for 
the Study of Lung Cancer/Association for Molecular Pathology 
(CAP/IASLC/AMP) [17]. The National Comprehensive Cancer 
Network (NCCN) guideline [18] was also referenced. The rec-
ommendations for HER2 (ERBB2) genotype tests were prepared 
on the basis of the American Society of Clinical Oncology (ASCO)/ 
CAP Clinical Practice guideline [19-21], the NCCN guideline [22], 
the Spanish Society of Pathology (SEAP), the Spanish Society of 
Medical Oncology (SEOM) guideline [23], and the United King-
dom (UK) Recommendation [24]. The recommendations for 
KRAS genotype tests were prepared on the basis of the NCCN 
guideline [18], the ASCO Provisional Clinical Opinion [25], the 
European Society for Medical Oncology (ESMO) Clinical Practice 
guideline [26], the 2010 European Science Foundation-Univer-
Kim S, et al.
Clinical pharmacogenetic testing guidelines
182  www.annlabmed.org https://doi.org/10.3343/alm.2017.37.2.180
sity of Barcelona (ESF-UB) Conference on Pharmacogenetics 
and Pharmacogenomics [27], the Italy Recommendation [28], 
and the SEAP and SEOM guidelines [29]. 
1. CYP2C9 and VKORC1 genes and warfarin 
1) Recommendation
For warfarin treatment, it is recommended that CYP2C9 and 
VKORC1 genotype tests be performed for proper individualized 
drug dosing.
2) Rationale
Warfarin is the most commonly prescribed oral anticoagulation 
agent. It has excellent efficacy, but it also has a narrow thera-
peutic index, and the success of treatment varies among indi-
viduals, making it difficult to determine the dose [30-32]. There 
is also a high risk of complications from warfarin treatment; the 
patient can become over-anticoagulated or under-anticoagu-
lated during this period, leading to a much greater risk of throm-
boembolism or hemorrhage.
CYP2C9 is a drug-metabolizing enzyme belonging to the cyto-
chrome P450 (CYP) superfamily. This enzyme is expressed in 
the liver and is the major metabolic enzyme of S-warfarin. Ho-
mozygous wild-type CYP2C9*1 shows normal enzyme activity. 
The most common variants with reduced enzyme activity in the 
Western population are CYP2C9*2 (rs1799853) and CYP2C9*3 
(rs1057910) [33]; in the Asian population, including Koreans, 
there have been no reports of CYP2C9*2 (rs1799853) [33, 34]. 
CYP2C9*2 and CYP2C9*3 have been reported to reduce S-war-
farin metabolism by about 30–40% and 80–90%, respectively, 
in in vitro and in vivo studies [33]. Patients with CYP2C9*2 or 
CYP2C9*3 alleles are at a greater risk of hemorrhage during war-
farin treatment [30, 35, 36] than those with homozygous wild-
type CYP2C9*1 alleles, and therefore should receive a lower dose. 
Patients with CYP2C9*2 or CYP2C9*3 alleles also require more 
time until the prothrombin time international normalized ratio 
(PT INR) is stabilized [35, 37].
The VKORC1 gene encodes the vitamin K epoxide reductase, 
which is the target enzyme of warfarin [38, 39]. Vitamin K epox-
ide reductase is involved in reducing vitamin K epoxide to vita-
min K, which is the rate-limiting step of the vitamin K circuit [40]. 
The typical non-coding variant c.-1639G>A (VKORC1 G3673A, 
rs9923231) changes a transcription factor binding site in the 
VKORC1 gene and thus reduces gene transcription [32, 41], 
which is closely related to the low warfarin dose requirement 
[32, 34, 41-44]. 
In Asian populations, including Koreans, the CYP2C9*3 vari-
ant should be the first CYP2C9 variant tested. For the VKORC1 
gene, VKORC1 -1639G>A should be tested directly or the c.174-
136C>T (VKORC1 1173C>T, rs9934438) variant should be 
tested because it exhibits complete linkage disequilibrium with 
the VKORC1 -1639G>A variant. Allele frequencies of CYP2C9 
and VKORC1 in the Korean population are 0% for CYP2C9*2, 
4–5% for CYP2C9*3, and 87–94% for VKORC1 1173C>T. 
The average maintenance dose based on CYP2C9 and VKORC1 
genotype as recommended by the U.S. Food and Drug Admin-
istration (FDA)-approved warfarin (Coumadin) labeling is sum-
marized in Table 1. Within each dose range, the patients’ age, 
body surface area, interacting drugs, and other major factors 
should be considered when determining drug dosage. Addition-
ally, when administering warfarin, application of a genotype-based 
dosing algorithm that determines the warfarin maintenance dose 
based on CYP2C9 and VKORC1 genotypes is recommended 
[45]. The International Warfarin Pharmacogenetics Consortium 
(IWPC) algorithm [44] and Gage [43] algorithm are commonly 
used. These algorithms include genotype information and clini-
cal information so that the warfarin maintenance dose required 
in a stable state can be more accurately predicted [43, 44]. Such 
genotype-based dosing algorithms have a greater predictive power 
for the proper maintenance dose than the fixed dose method or 
the traditional clinical algorithm.
Most genotype-based dosing algorithms target PT INR 2–3, 
so it is difficult to apply these algorithms when the target INR 
Table 1. Recommended warfarin doses (mg/day) to achieve a therapeutic INR based on CYP2C9 and VKORC1 genotype using the warfa-
rin product insert approved by the United States Food and Drug Administration  [5, 92]
VKORC1-1639G>A CYP2C9*1/*1 CYP2C9*1/*2 CYP2C9*1/*3 CYP2C9*2/*2 CYP2C9*2/*3 CYP2C9*3/*3
GG 5–7 5–7    3–4    3–4    3–4 0.5–2
GA 5–7 3–4    3–4    3–4 0.5–2 0.5–2
AA 3–4 3–4 0.5–2 0.5–2 0.5–2 0.5–2
Adapted from Johnson JA, et al. Clin Pharmacol Ther 2011;90:625-9 [5] and Whirl-Carrillo M, et al. Clin Pharmacol Ther 2012;92:414-7 [92], with permis-
sion of the PharmGKB and Stanford University.
Abbreviation: INR, international normalized ratio.
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lies outside this range [46]. Even if drug is administered accord-
ing to the genotype-based dosing algorithm, PT INR must be 
monitored [5]. For children, there are almost no data regarding 
the related algorithms or the influence of CYP2C9 and VKORC1 
genotype on the warfarin dose [47]. There is no warfarin dosing 
recommendation for children. The benefit of genotype testing is 
low for patients who have stably taken warfarin over a long pe-
riod, for patients having difficulty achieving a stable dose due to 
poor compliance, or for patients who are on a diet including vi-
tamin K. Genotype testing to determine the correct dose is most 
effective before treatment begins or at the initial stages of treat-
ment [48]. 
2. CYP2C19 gene and clopidogrel 
1) Recommendation
The use of CYP2C19 genotype tests is recommended in cases 
of anti-platelet agent treatment in patients with acute coronary 
artery syndrome who have received or are planning to receive 
percutaneous coronary intervention.
2) Rationale
Clopidogrel is converted to its active form by various CYP enzymes 
to suppress platelet aggregation, leading to an antiplatelet effect. 
In particular, activation of the CYP2C19 enzyme determines the 
rate of conversion from clopidogrel into its active form. Thus, the 
incidence of stent thrombosis and major complications of acute 
coronary artery syndrome differs among patients [7]. When clopi-
dogrel is used for treatment, lower CYP2C19 activation leads to 
fewer circulating active metabolites, thus reducing its suppressive 
effect on platelet aggregation. Therefore, the use of CYP2C19 
genotype testing is recommended to predict a patient’s response 
to clopidogrel or to consider alternative drugs.
Homozygous wild-type CYP2C19*1 has normal enzyme activ-
ity. Individuals with heterozygous and homozygous CYP2C19*2 
genotypes have 1.55 times and 1.76 times greater risk of suffer-
ing from major cardiovascular diseases, respectively, than pa-
tients with homozygous wild-type CYP2C19*1 [49]. Additionally, 
stent thrombosis likelihood is increased by 2.67 times in indivi-
duals with the heterozygous variant and by 3.97 times in those 
with the homozygous variant [49]. In conditions, such as atrial 
fibrillation, cerebral infarction, or stable angina, an association 
between reduced activities from CYP2C19 gene variants with the 
risk of cardiovascular side effects has not been established. It has 
been reported in the West that the frequency of the CYP 2C19*3 
variant is low, but this variant does reduce the response to clopi-
dogrel [50]. In studies on Chinese and Korean populations, the 
CYP2C19*3 variant was reported to reduce the reactivity to lev-
els similar to those of the CYP2C19*2 variant [51-56].
Variants in CYP2C19 are found across the whole gene, but 
since typical variants causing enzyme dysfunction are known, it 
is reasonable to test these alleles first. The CYP2C19*2 and CYP2 - 
C19*3 alleles are the most frequent, but most alleles of the CYP - 
2C19 gene reduce the metabolic rate of clopidogrel. On the other 
hand, the CYP2C19*17 allele increases the metabolic rate of 
clopidogrel. The frequency of CYP2C19*3 in the Korean popu-
lation is relatively high, at 7–10%, but this variant is rarely de-
tected in the West. In contrast, the frequency of CYP2C19*17 
in Koreans, which is relatively common in the West, is very low, 
at about 1%. The phenotypes resulting from the CYP2C19 gen-
otypes are classified into four categories (Table 2): extensive me-
tabolizer (EM), poor metabolizer (PM), intermediate metabolizer 
(IM), and ultra-rapid metabolizer (UM). The phenotype is cate-
gorized as EM for homozygous wild-type CYP2C19*1, IM for 
CYP2C19*1 and CYP2C19*2/*3 heterozygous variants, PM for 
two dysfunctional alleles (CYP2C19*2, CYP2C19*3, etc.), and 
UM for the homozygous CYP2C19*17 variant or heterozygous 
CYP2C19*1 and CYP2C19*17 variants.
For patients classified as PM or IM by CYP2C19 genotype tests, 
the administration of recently developed antiplatelet agents such 
as prasugrel or ticagrelor can be considered instead of clopido-
grel (Table 2). In IM cases, it has been reported that during clopi-
dogrel treatment, the remaining platelet activity is increased and 
the risk of serious cardiovascular side effects is increased; how-
ever, because interindividual variation is significant, it is best to 
consider other clinical factors. There is not yet enough evidence 
on the effects of increased clopidogrel dose in patients expected 
to show reduced clopidogrel metabolism based on CYP2C19 geno-
type analysis [7]. When the use of proton pump inhibitors is com-
bined with clopidogrel, CYP2C19 enzyme activity is suppressed, 
and the effect of clopidogrel can be influenced by reducing the 
generation of the active form of clopidogrel [7, 56].
3.  CYP2D6 gene and tricyclic antidepressants, codeine, 
tamoxifen, and atomoxetine 
1) Recommendation
When administering tricyclic antidepressants, codeine, tamoxi-
fen, or atomoxetine, the use of CYP2D6 genotype test is recom-
mended.
2) Rationale
The functionality of CYP2D6 in drug metabolism can be deter-
mined on the basis of patient’s CYP2D6 genotype. The side ef-
Kim S, et al.
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fects and safety of tricyclic antidepressants, codeine, tamoxifen, 
and atomoxetine vary according to differences in the metabo-
lism capacity of CYP2D6 based on the CYP2D6 genotype of the 
individual patient [8-10, 14, 57]. The drug removal rate or con-
version rate to active metabolites also differs depending on CYP - 
2D6 activity, thus, the risks of treatment failure or side effects 
may increase in different CYP2D6 variants.
Tricyclic antidepressants are compounds that inhibit the reab-
sorption of serotonin and norepinephrine; they are metabolized 
into hydroxyl metabolites with low activity by CYP2D6 [10]. Tri-
cyclic antidepressant metabolism is delayed in CYP2D6 PM so 
that the blood tricyclic antidepressant concentration increases, 
leading to the increased possibility of side effects, such as anti-
cholinergic actions, central nervous system disorders, heart func-
tion disorders, and other conditions. In UM, decreased blood 
tricyclic antidepressant concentration leads to the possibility of 
treatment failure [10].
Codeine is a narcotic analgesic. About 80% of the adminis-
tered codeine is converted into inactive metabolites, and about 
5–15% is metabolized by CYP2D6 into the active metabolite mor-
phine. Therefore, CYP2D6 metabolism is important for the anal-
gesic effect of codeine [8, 9]. Codeine conversion rate to mor-
phine is significantly decreased in CYP2D6 PM, so that the an-
algesic effect may be insufficient, whereas the rate of conver-
sion to morphine is increased in CYP2D6 UM, possibly increas-
ing drug side effects such as nausea, vertigo, drowsiness, seda-
tion, shortness of breath, constipation, pruritus, difficulty in breath-
ing, circulatory disorders, apnea, shock, or heart attack [8, 9].
Tamoxifen is a selective estrogen receptor modulator used for 
treating and preventing hormone-dependent breast cancer. Tam-
oxifen is a prodrug, and CYP2D6 is involved in its metabolism 
into endoxifen, which is the rate-limiting step. Endoxifen is an 
active metabolite with 30–100 times higher antiestrogen activity 
than tamoxifen. It has been suggested that variations in CYP2D6 
are involved in the individual differences in drug metabolism and 
response among patients, but there are inconsistent results across 
studies [14, 57, 58]. The blood endoxifen concentration decre-
ases owing to the reduced conversion of tamoxifen to endoxifen 
in CYP2D6 PM, accordingly, the risk of breast cancer recurrence 
is increased. In UM patients, the concentration of the active me-
tabolite increases, so the possibility of side effects is increased 
[13, 14]. There are large interindividual variations in endoxifen 
concentration, and this is thought to be partially due to CYP2D6 
gene variation [14, 57, 58].
Atomoxetine is used to treat attention deficit hyperactivity dis-
order (ADHD) in children, teenagers, and young adults. Atom-
oxetine is metabolized by CYP2D6 into hydroxyatomoxetine with 
low activity. The effect of atomoxetine may be reduced in CYP2D6 
UM patients. In PM, the half-life is significantly increased, so at-
omoxetine concentration is about five times higher than that of 
EM [14]. Therefore, the possibility of adverse drug reactions such 
as headache, insomnia, xerostomia, abdominal pain, nausea, 
Table 2. Clopidogrel therapy based on CYP2C19 genotype and phenotype for ACS/PCI patients initiating antiplatelet therapy [7, 92]
Likely phenotype Genotypes Examples of diplotypes Implications for clopidogrel Therapeutic recommendations
Ultra-rapid metabolizer: normal or 
increased activity (~5–30% of 
patients)
An individual carrying two 
increased-activity alleles 
(*17), or one functional allele 
(*1) plus one increased-
activity allele (*17)
*1/*17, *17/*17 Increased platelet inhibition, 
decreased residual platelet 
aggregation
Clopidogrel label-recommended 
dosage and administration
Extensive metabolizer: homozygous wild-
type or normal activity (~35–50% of 
patients)
An individual carrying two 
functional (*1) alleles
*1/*1 Normal platelet inhibition, 
normal residual platelet 
aggregation
Clopidogrel label-recommended 
dosage and administration
Intermediate metabolizer: heterozygote or 
intermediate activity (~18–45% of 
patients)
An individual carrying one 
functional allele (*1) plus one 
loss-of-function allele (*2–*8)
*1/*2, *1/*3 Reduced platelet inhibition, 
increased residual platelet 
aggregation, increased risk for 
adverse cardiovascular events
Prasugrel or other alternative 
therapy (if no contraindication)
Poor metabolizer: homozygous variant, 
mutant, low, or deficient activity  
(~2–15% of patients)
An individual carrying two loss-
of-function alleles (*2–*8)
*2/*2, *2/*3, *3/*3 Significantly reduced platelet 
inhibition, increased residual 
platelet aggregation, increased 
risk for adverse cardiovascular 
events
Prasugrel or other alternative 
therapy (if no contraindication)
Adapted from Scott SA, et al. Clin Pharmacol Ther 2013;94:317-23 [7] and Whirl-Carrillo M, et al. Clin Pharmacol Ther 2012;92:414-7 [92], with permis-
sion of the PharmGKB and Stanford University.
Abbreviation: ACS/PCI, acute coronary syndrome/percutaneous coronary intervention.
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reduced appetite, or coughing increases. When taken with CYP - 
2D6 inhibitors, such as paroxetine or fluoxetine, the atomoxetine 
metabolism is suppressed, so that adverse effects similar to those 
associated with CYP2D6 PM may occur [14].
To determine the CYP2D6 genotype, a test for large gene de-
letions/duplications, such as long PCR or multiplex ligation-de-
pendent probe amplification (MLPA), should be conducted along-
side a test for single-nucleotide variants. When testing in Kore-
ans, a method that can detect CYP2D6*10, gene deletions (CYP- 
2D6*5) and amplification (xN) should be included.
Based on the activity score calculated from the combinations 
of CYP2D6 alleles, the CYP2D6 phenotype can be determined 
[59, 60]. The recommendations for tricyclic antidepressant treat-
ment based on CYP2D6 phenotype are shown in Table 3.
The codeine treatment recommendations based on CYP2D6 
phenotype are as follows: in UM, owing to the high possibility of 
adverse drug effects, the use of codeine should be avoided, and 
the use of an alternative analgesic agent should be considered. In 
IM, treatment is initiated at the usual dose, and the use of an al-
ternative analgesic agent should be considered if pain is not miti-
gated. In the case of PM, the drug effect could be reduced, so the 
use of an alternative analgesic agent should be considered [8]. 
For tamoxifen, established administration recommendations 
are not available, but the DPWG guideline recommends an aro-
matase inhibitor for post-menopausal breast cancer patients [13], 
on the basis of clinical studies [61, 62]. 
In case of atomoxetine in EM, the recommended atomoxetine 
dose is 1.2 mg/kg/day for a body weight of 70 kg or below and 
80 mg/kg/day for a body weight of 70 kg or above. In PM, the 
recommendation is 0.5 mg/kg/day for a body weight of 70 kg or 
below and 40 mg/day for a body weight of 70 kg or above [14].
Table 3. Assignment of likely phenotypes based on diplotypes of CYP2D6 and dosing recommendations for amitriptyline based on CYP2D6 
phenotype [10, 92]
Likely phenotype Activity score Genotypes Examples of diplotypes Implications  Therapeutic recommendation
Ultra-rapid 
metabolizer 
(~1–2%)
>2.0 An individual carrying 
duplications of functional 
alleles
(*1/*1)xN, (*1/*2)xN, 
(*2/*2)xNc
Increased metabolism of tricyclics 
to less active compounds when 
compared with extensive 
metabolizers. 
Lower plasma concentrations will 
increase probability of 
pharmacotherapy failure.
Avoid tricyclic use due to potential 
lack of efficacy. Consider 
alternative drug not metabolized by 
CYP2D6. 
If a tricyclic is warranted, consider 
increasing the starting dose. Utilize 
therapeutic drug monitoring to 
guide dose adjustments.
Extensive 
metabolizer 
(~77–92%)
1.0–2.0 An individual carrying 2 
functional alleles or 1 
functional and 1 
nonfunctional allele or 1 
functional and 1 
reduced-function allele
*1/*1, *1/*2, *2/*2, 
1/*9, *1/*41, *1/*5, 
*1/*4
Normal metabolism of tricyclics. Initiate therapy with recommended 
starting dose.
Intermediate 
metabolizer  
(~2–11%)  
0.5 An individual carrying 1 
reduced- function and 1 
nonfunctional allele or 2 
reduced-function alleles
*4/*41, *5/*9, *4/*10, 
*41/*41
Reduced metabolism of tricyclics 
to less active compounds when 
compared with extensive 
metabolizers. 
Higher plasma concentrations 
increase the probability of side 
effects.
Consider a 25% reduction in 
recommended starting dose. Utilize 
therapeutic drug monitoring to 
guide dose adjustments.
Poor metabolizer  
(~5–10%)
0 An individual carrying no 
functional alleles
*4/*4, *3/*4, *5/*5, 
*5/*6
Greatly reduced metabolism of 
tricyclics to less active 
compounds when compared with 
extensive metabolizers. 
Higher plasma concentrations 
increase the probability of side 
effects.
Avoid tricyclic use due to potential for 
side effects. Consider alternative 
drug not metabolized by CYP2D6. 
If a tricyclic is warranted, consider a 
50% reduction in recommended 
starting dose. Utilize therapeutic 
drug monitoring to guide dose 
adjustments.
Adapted from Hicks JK, et al. Clin Pharmacol Ther 2013;93:402-8 [10] and Whirl-Carrillo M, et al. Clin Pharmacol Ther 2012;92:414-7 [92], with permis-
sion of the PharmGKB and Stanford University.
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4. NAT2 gene and isoniazid 
1) Recommendation
When administering the anti-tuberculosis drug isoniazid, the use 
of NAT2 genotype tests is recommended.
2) Rationale
Isoniazid is one of the first-line treatment regimens for tubercu-
losis. It is metabolized primarily in the liver by arylamine N-acet-
yltransferase 2 (NAT2). Hepatitis is a common adverse effect of 
isoniazid administration. The risk of drug-induced hepatotoxicity 
varies depending on acetylation status determined by NAT2 gene 
alleles [63-65]. 
The wild-type NAT2 allele is NAT2*4 [66]. The Korean popu-
lation shows a lower frequency of the NAT2*5 allele, which is 
common in other races, but it has a relatively high frequency of 
the NAT2*6 (c.590G>A) and NAT2*7 (c.857G>A) alleles, which 
show reduced NAT2 enzyme activity. The phenotypes are di-
vided into three types according to the number of alleles, and 
the enzyme activity of each genotype is shown in Table 4. The 
cases with two rapid alleles (such as NAT2*4), one rapid allele 
and one slow allele (such as NAT2*6 or NAT2*7), and two slow 
alleles are classified into the rapid acetylators, intermediate acet-
ylators, and slow acetylators, respectively. Also, cases with at 
least one or more wild-type allele (NAT2*4) are classified into 
the rapid acetylator group, and all other cases or the cases with 
no NAT2*4 allele are classified into the slow acetylator group in 
other publications [16, 67]. Phenotype frequencies of NAT2 gene 
variations in the Korean population are 39–45% for rapid acetyl-
ators, 44–50% for intermediate acetylators, and 8–11% for slow 
acetylator [68, 69].
NAT2 activity is determined by the number of active alleles. 
Decreased acetylation is associated with a reduced isoniazid 
clearance rate, thus increasing exposure to the drug and its re-
lated metabolites. The risk of drug-induced hepatotoxicity is higher 
in the slow acetylator group, in which the activity of both NAT2 
alleles is reduced, than it is in the rapid acetylator group, which 
has normal allele activity [16, 70, 71]. Meta-analysis has shown 
that, although the odds ratio for the drug-induced hepatotoxicity 
of the NAT2 slow acetylator group has been reported to be 3.32 
(95% confidence interval 2.43–4.53) in East Asians, no correla-
tion has been found in Caucasians [16].
There is currently no agreement on appropriate isoniazid dos-
ing based on NAT2 genotype or phenotype because of few clini-
cal studies; however, a recommendation for dosing based on the 
genotype may be used if data are accumulated in the future. In 
a recent randomized control study in Japan and Korea, NAT2 
genotype and phenotype-based isoniazid dosing for an anti-tu-
berculosis therapy was suggested [70, 72]. In the slow acetyla-
tion group, there was no loss in treatment efficacy when a re-
duced dose was administered, but drug-induced hepatotoxicity 
decreased. In the rapid acetylation group, the initial treatment 
failure rate decreased without increased hepatotoxicity when in-
creasing the dose. So far, however, there has been no establish ed 
recommendation, and future studies are necessary. During anti-
tuberculosis treatment, measuring blood drug concentration may 
be helpful when the effects of treatment are inadequate as a re-
sult of drug absorption, administration compliance, and com-
bined medication influence [73, 74]. 
5. UGT1A1 gene and irinotecan
1) Recommendation
For high-dose irinotecan therapy (>250 mg/m2), the use of UG- 
T1A1 genotype testing is recommended before treatment to help 
determine the proper initial dose and prevent drug-related ad-
verse reactions [14]. According to the recent review by French 
joint working group, pretreatment UGT1A1 genotyping is rec-
ommended for all patients scheduled to receive an irinotecan 
dose ≥180 mg/m2 [75].
2) Rationale
Irinotecan is used for treating metastatic colon cancer and other 
solid cancers. It is glucuronated by the uridine diphosphate gluc-
uronosyl-transferase (UGT) 1A1 enzyme in liver cells and is ex-
creted into bile in its inactive state. When UGT1A1 enzyme ac-
tivity is decreased, the active metabolite 7-ethyl-10-hydroxyc-
amptothecin (SN-38) may cause irinotecan-related adverse ef-
fects due to decreased metabolism and excretion.
Owing to the variation in drug metabolism when administering 
Table 4. Assignment of likely phenotypes based on diplotypes of NAT2 [66, 68, 69]
Likely phenotype Genotype Examples of diplotypes
Normal/high activity (rapid acetylator, 39-45%) An individual carrying two rapid NAT2 alleles (*4, *11, *12, *13) *4/*4, *4/*12, *4/*13
Intermediate activity (intermediate acetylator, 44-50%) An individual carrying one rapid NAT2 allele plus one slow NAT2 allele *4/*5, *4/*6, *4/*7
Low activity (slow acetylator, 8-11%) An individual carrying two slow NAT2 alleles (*5, *6, *7) *6/*6, *7/*7, *6/*7, *5/*6, *5/*7
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irinotecan based on the UGT1A1 genotype, serious side effects 
such as severe neutropenia or diarrhea may occur. It has been 
reported that the relative risk of neutropenia is 2.0–7.2 times 
higher in people homozygous for the UGT1A1*28 allele than in 
those with the homozygous wild-type genotype, and this risk in-
creases with a higher dose of irinotecan [76]. The UGT1A1*6 
allele, which is relatively common in Asians, is also related to iri-
notecan-induced toxicity [77, 78]. Therefore, in Asian patients, 
it is desirable to check for both UGT1A1*28 and UGT1A1*6 
when conducting UGT1A1 genotype tests. The allele frequen-
cies of UGT1A1 in the Korean population are 18.6–22.2% for 
UGT1A1*6 and 9.5–12.7% for UGT1A1*28 [79-81]. Genotype 
tests should be used in addition to treatment policy determina-
tion and cannot replace the clinician’s decision and clinical ex-
perience. Additionally, other important factors such as liver func-
tion, kidney function, age, and concurrently used medicine, should 
be considered.
The enzyme activity according to each UGT1A1 genotype and 
phenotype is shown in Table 5. When administering a high dose 
of irinotecan (250 mg/m2 or greater) to patients who are homo-
zygous for the UGT1A1*28 variant allele, administration of a dose 
that is 1 degree lower (e.g. 125 mg/m2) [14] or a dose that is 
decreased by 30% is recommended [13]. For patients with the 
UGT1A1*28 heterozygous variant, reducing the dose may cause 
under-treatment, so it is not recommended [13]. UGT1A1*6 
also reduces the activity of the UGT1A1 enzyme, but there has 
not been an established recommendation on drug dose control 
in patients with UGT1A1*6 [82]. 
6.  TPMT gene and thiopurine family drugs (azathioprine, 
mercaptopurine, and thioguanine)
1) Recommendation
TPMT genotyping before administering thiopurines (azathioprine, 
mercaptopurine, and thioguanine) is recommended to determine 
the proper initial dosing.
2) Rationale
Azathioprine is used mainly to treat immune diseases, including 
inflammatory bowel disease, mercaptopurine is used to treat im-
mune diseases and lymphoid malignancies, and thioguanine is 
used to treat myelogenous leukemia. Azathioprine is metabolized 
into mercaptopurine, most of which is converted into the inac-
tive form methyl-mercaptopurine (methylMP) by thiopurine S-
methyltransferase (TPMT). A small amount of mercaptopurine 
goes through multiple stages of metabolism, being converted 
into methyl-thioinosine monophosphate (methylTIMP), which 
results in immunosuppression and hepatotoxicity, and the major 
active form of thioguanine nucleotide (TGN) [11, 83, 84]. 
The lower the TPMT activity, the more the blood TGN level in-
creases when thiopurines are used. In homozygous variants that 
carry two nonfunctional TPMT alleles, administering a conven-
tional dose of azathioprine and mercaptopurine maintains a high 
TGN concentration and thus results in severe life-threatening 
myelosuppression (myelosuppression risk 100%). In cases of 
heterozygotes with a single nonfunctional TPMT allele, there is a 
moderate to severe myelosuppression risk (30–60%). In homo-
zygous wild-type patients with two functional alleles, the risk of 
myelosuppression is relatively low [12, 85]. When using thiopu-
rines in patients with low TPMT activity, late-developing adverse 
effects such as secondary cancers may occur even if severe my-
elosuppression does not occur. There have been no reports as-
sociating the adverse effects of reduced TMPT activity with drugs 
other than thiopurines, and pancreatitis and hepatotoxicity have 
not been found to be related to low TMPT activity [12]. 
Although 30 or more TPMT alleles are known, only a few al-
leles that cause reduced enzyme activity are prevalent. Thus, 
common alleles can be preferentially selected to perform TPMT 
genotyping [86]. The TPMT*3 has the highest prevalence (0.8–
2.5%) in the Korean population, but the presence of *6, *16, 
*32, and *38 has been reported [87]. The TPMT phenotypes 
based on each genotype are described in Table 6. 
Table 5. Assignment of likely phenotypes based on diplotypes of UGT1A1 [15, 92]
Likely phenotype Genotype Examples of diplotypes
Extensive metabolizer: homozygous wild-type or normal 
activity
An individual carrying two function (*1) and/or increased function alleles (*36) *1/*1
Intermediate metabolizer: heterozygote or intermediate 
activity
An individual carrying one function (*1) or increased function allele (*36) plus one 
decreased function allele (*6, *28)
*1/*6, *1/*28
Poor metabolizer: compound heterozygote, homozygous 
variant or low activity
An individual carrying two decreased function alleles (*6, *28) *6/*6, *28/*28,*6/*28
Adapted from Gammal RS, et al. Clin Pharmacol Ther 2016;99:363-9 [15] and Whirl-Carrillo M, et al. Clin Pharmacol Ther 2012;92:414-7 [92], with per-
mission of the PharmGKB and Stanford University.
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When dosing is appropriately controlled on the basis of TPMT 
genotype and phenotype, the anticancer and immunosuppres-
sive effects of thiopurines can be maintained while reducing the 
adverse effects. Toxicity can also be reduced without increased 
risk of recurrence in patients with acute lymphoblastic leukemia. 
Although the number of patients with TPMT variants is small, 
there are many cases where thiopurines are administered along-
side other drugs, inducing myelosuppression. These cases may 
result in severe adverse effects such as fatality or myelosuppres-
sion even after a short conventional dose of thiopurines in pa-
tients with homozygous variants. Therefore, TPMT genotyping 
before initiating thiopurine treatment is recommended to deter-
mine the initial dose.
In cases where a conventional dose is administered in TPMT 
heterozygous variants, only 30–60% of patients show myelosup-
pression, and administering a reduced dose to all patients leads 
to the undertreatment of a portion of patients who would not 
have shown adverse effects. Therefore, to minimize undertreat-
ment until the steady state is reached, the patient’s state, con-
comitant medications, adverse effects, and disease progression 
should be monitored to adjust the dose. Therapeutic drug moni-
toring (TDM) can be performed by measuring the thiopurine me-
tabolites of TGN and the methylMP in peripheral blood erythro-
cytes. This can help to evaluate treatment compliance and the 
influence of concomitant medications, as well as to assist in judg-
ing whether thiopurine administration decreases leukocytes [12, 
88]. 
7.  EGFR gene and non-small-cell lung cancer
1) Recommendation
To select non-small-cell lung cancer patients who are candidates 
for tyrosine kinase inhibitor (TKI) treatment—a treatment agent 
for targeting the epidermal growth factor receptor (EGFR)—the 
use of EGFR gene testing is recommended.
2) Rationale
The European Medicines Agency stipulates that EGFR gene test-
ing must be performed when using TKIs, especially gefitinib. Ac-
cording to Korean Association for Lung Cancer (KASLC) clinical 
guidelines, in non-small-cell lung cancer cases where there is an 
EGFR gene mutation, gefitinib or erlotinib is prescribed as the 
primary anticancer treatment. In cases where there are no muta-
tions, platinum-based chemotherapy is recommended. The usage 
precautions for gefitinib (Iressa) outlined by the Korea Food and 
Drug Administration state that it is important to select a properly 
verified and established method to avoid false negative or false 
positive results when evaluating a patient’s EGFR mutation state.
A non-small-cell lung cancer patient with an active mutation 
in exons 18-21 of the EGFR gene will respond to TKIs, and their 
average life expectancy is extended. An in-frame deletion in exon 
19 (amino acids 729–761) and L858R located in exon 21 are 
the most common mutations that result in drug sensitivity, and 
these are responsible for approximately 90% of cases [17, 18]. 
A significant number of patients react to initial TKI treatment, 
however, they acquire drug tolerance during treatment. T790M, 
located in exon 20, is associated with acquired resistance. The 
T790M mutation is rarely detected in patients before treatment. 
In rare cases, it can be discovered as a germline mutation in cases 
of familial lung cancer [17, 18].
The EGFR mutation is present in Asians at a frequency of ap-
proximately 30–40% and in Caucasians at a frequency of ap-
proximately 10–15%. EGFR mutations also are frequent in non-
smokers and females. However, clinical information (e.g., smok-
ing, gender, or race) is not sufficiently sensitive to select patients 
for TKI treatment or EGFR testing, and it is recommended that 
such testing be performed on all target patients [17, 18]. 
EGFR genetic testing can be performed by using paraffin-em-
bedded, fresh, frozen, or alcohol-fixed tissue or body fluid speci-
mens. A pharmacogenetic method that can detect mutations in 
specimens with at least 50% tumor cells must be used [17]. The 
use of a testing method that can detect mutations in specimens 
Table 6. Assignment of likely thiopurine S-methyltransferase (TPMT) phenotypes based on genotype [12, 92]
Likely phenotype Genotypes Examples of diplotypes
Homozygous wild-type or normal, high activity 
(constitutes ~86–97% of patients)
An individual carrying two or more functional (*1) 
alleles
*1/*1
Heterozygote or intermediate activity  
(~3–14% of patients)
An individual carrying one functional allele (*1) plus 
one nonfunctional allele (*2, *3A, *3B, *3C, or *4)
*1/*2, *1/*3A, *1/*3B, *1/*3C, *1/*4
Homozygous variant, mutant, low, or deficient activity 
(~1 in 178 to 1 in 3,736 patients)
An individual carrying two nonfunctional alleles  
(*2, *3A, *3B, *3C, or *4)
*3A/*3A, *2/*3A, *3C/*3A, *3C/*4, *3C/*2, *3A/*4
Adapted from Relling MV, et al. Clin Pharmacol Ther 2011;89:387-91 [12] and Whirl-Carrillo M, et al. Clin Pharmacol Ther 2012;92:414-7 [92], with per-
mission of the PharmGKB and Stanford University.
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with as little as 10% tumor cells is strongly recommended. To 
detect acquired T790M mutations, the testing method should 
be able to detect the mutation in as few as 5% of cells [17]. Such 
a method should be able to detect all gene mutations that have 
been reported to be showing a frequency of at least 1% of EGFR-
mutated lung cancers. In the case of testing with the purpose of 
selecting TKI targets, immunohistochemistry (IHC) is not recom-
mended. 
One should ascertain if the detected mutation is an active mu-
tation or a resistance mutation based on the TKI phenotype for 
each EGFR mutation organized in Table 7. 
8. HER2 gene and breast cancer
1) Recommendation
To determine whether to use HER2 targeted therapy in breast 
cancer patients, in situ hybridization (ISH) is recommended to 
determine HER2 gene amplification or IHC is recommended to 
check HER2 protein overexpression.
2) Rationale
HER2 overexpression is observed in 15–20% of breast cancer 
cases, and cases positive for HER2 overexpression respond to 
HER2-targeted treatment [20]. Thus, the presence of HER2 over-
expression can determine the therapeutic response to HER2-
targeted treatment. Therefore, in patients with invasive breast 
cancer, it is recommended that HER2 gene amplification or HER2 
overexpression testing be performed before anti-HER2 therapy, 
and that only those patients who exhibit HER2 overexpression 
be administered anti-HER2 therapy.
HER2 is a gene that encodes proteins belonging to the EGFR 
family of tyrosine kinase receptors, and this gene is also called 
HER2, NEU, NGL, TKRI, Her-2, c-erb B2, and Her-2/new. HER2 
gene amplification is the major mechanism that leads to HER2 
overexpression; there is a rise in the concentration of 185 kDa 
glycoproteins with tyrosine kinase activity in tumors with HER2 
gene amplification. HER2 overexpression is related to the clini-
cal outcome of breast cancer patients, and it is a powerful pre-
dictor for determining the response to the anti-HER2 therapy. In 
case of HER2 overexpression, anti-HER2 therapies, such as trast-
uzumab (Herceptin), lapatinib, pertuzumab, or trastuzumab em-
tansine (KADCYLA), can be used. Therefore, it is recommended 
that HER2 testing be performed for all patients with invasive (early 
stage or recurrent) breast cancer and that anti-HER2 therapy 
be applied only to those cases with positive test results.
HER2 testing uses cancer tissue of the primary or recurring 
cancer or metastatic area, obtained through an operation or nee-
dle biopsy. The time between tissue acquisition and fixation should 
be minimized (within one hour), and the specimen should be 
fixed in neutral buffered formalin for 6-72 hr. Tissue sections 
should not be used for HER2 testing if cut more than six weeks 
earlier [20]. 
HER2 testing uses both IHC and ISH. IHC is used to examine 
HER2 expression, and fluorescent in situ hybridization (FISH) or 
silver in situ hybridization (SISH) is used to examine gene expres-
sion. If pre-analytical or analytical requirements are not satisfied 
or quality assurance fails, the test should be considered inappro-
priate for HER2 assessment. 
HER2 testing results are either positive, equivocal, negative, 
or indeterminate. HER2-positive is defined as cases where pro-
tein overexpression was determined by IHC by observing expres-
sion in at least 10% of contiguous and homogenous tumor cells 
within the tumor area or in cases where gene amplification was 
observed by ISH (HER2 copy number or HER2/CEP17 ratio based 
on a cell count of 20 or more within the area) has been confirmed.
Table 7. Drug sensitivity based on EGFR genetic variation 
Major genetic variation Nomenclature Phenotype
G719S (exon 18) NM_005228.3:c.2155G<A, NP_005219.2:p.Gly719Ser TKI sensitivity
G719C (exon 18) NM_005228.3:c.2155G<T, NP_005219.2:p.Gly719Cys TKI sensitivity
G719A (exon 18) NM_005228.3:c.2155G<C, NP_005219.2:p.Gly719Ala TKI sensitivity
In-frame deletions (exon 19) NM_005228.3:c.2235_2249del15, NP_005219.2:p.Glu746_Ala750del
NM_005228.3:c.2236_2250del15, NP_005219.2:p.Glu746_Ala750del
NM_005228.3:c.2239_2248delinsC, NP_005219.2:p.Leu747_Ala750delinsPro
NM_005228.3:c.2240_2257del18, NP_005219.2:p.Leu747_Pro753delinsSer
TKI sensitivity
TKI sensitivity
TKI sensitivity
TKI sensitivity
T790M (exon 20) NM_005228.3:c.2369C>T, NP_005219.2:p.Thr790Met TKI resistance
L858R (exon 21) NM_005228.3:c.2573T>G, NP_005219.2:p.Leu858Arg TKI sensitivity
L861Q (exon 21) NM_005228.3: c.2582T>A, NP_005219.2:p.Leu861Gln TKI sensitivity
Abbreviations: EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
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Patients with positive results from HER2 testing can undergo 
HER2-targeted treatment. When the result of the primary test is 
ambiguous, the same specimen should be checked through an 
alternative testing method (IHC or ISH) or testing should be per-
formed on an alternative specimen. If there is a histopathologi-
cal discordance, additional HER2 testing should be considered, 
and the decision-making process and results should be reported.
9.  KRAS gene and metastatic colorectal cancer 
1) Recommendation
In metastatic colorectal cancer patients, the use of the KRAS 
gene test is recommended to predict the therapeutic effects of 
anti-EGFR-targeted drugs (cetuximab and panitumumab).
2) Rationale
In about 40% of colorectal cancer cases, mutations are found 
in codons 12 and 13 in exon 2 of the KRAS gene. If these mu-
tations are present, there will likely be no response to EGFR-tar-
geted treatment. Therefore, it is strongly recommended that the 
KRAS gene test is performed on the cancer tissue (primary can-
cer tissue or metastatic cancer tissue) of all stage 4 metastatic 
colorectal cancer patients when beginning treatment.
Among the three types of the RAS gene family (HRAS, NRAS, 
and KRAS), KRAS mutations are most commonly found in color-
ectal cancer. GTPase, including RAS, normally hydrolyze GTP 
into GDP to maintain inactivity; however, when KRAS is mutated, 
GTPase activity is blocked, thus continually activating RAS. Most 
mutations occur at codons 12 and 13 and, in rare cases, at co-
don 61.
KRAS testing is used to establish the proper treatment contin-
uum by rapidly checking the KRAS state in early stages rather 
than selecting the preferred regimen. Because anti-EGFR drugs 
are not used to treat patients with colorectal cancer in stages 
1–3, the KRAS gene test is also not recommended for these pa-
tient groups. For KRAS wild-type metastatic colorectal cancer 
patients, adding anti-EGFR antibody to the anticancer treatment 
results in a higher overall response rate and a longer overall sur-
vival period compared with the anticancer drug-only treatment 
[29]. Although there is some controversy that codon 13 muta-
tions (p.G13D) cannot predict treatment non-response [89, 90], 
these are hypothetical and require further prospective studies. 
Therefore, the use of anti-EGFR drugs is not currently accepted 
as a conventional treatment for patients with p.G13D mutations. 
Additionally, since there are some cases where anti-EGFR drugs 
show no effect on patients with wild-type KRAS, the issue of whe-
ther there is an appropriate additional biological indicator for ce-
tuximab or panitumumab sensitivity other than KRAS testing is 
being studied. The frequency of KRAS codon 12 and 13 muta-
tions in colorectal cancer patients is 39.3%, and the most com-
mon mutations are p.G12D (36%) and p.G12V (21.8%), both 
in codon 12 [91]. Ethnic differences in KRAS mutation frequency 
have not been established.
KRAS mutation testing is performed by using specimens ob-
tained from surgery (primary or metastatic colorectal cancer tis-
sue), endoscopic biopsy, or thin-needle aspiration samples; this 
can be done by using frozen or paraffin-embedded tissue. There 
is no established standard for determining the amount of tumor 
cells within the specimen that is necessary for the KRAS gene 
test; however, as testing technology advances, the required tu-
mor cell amount is decreasing. It is desirable to use at least six 
to 10 tissue pieces that are 5 μm in size, and when possible, it 
is also desirable to use a specimen with high tumor cell amount.
KRAS mutation occurs in early stages of colorectal cancer for-
mation, so there is no large difference in the mutation state of 
the primary cancer tissue and the metastatic cancer tissue. There-
fore, the KRAS gene testing can be performed by using either 
the stored primary cancer tissue or the metastatic cancer tissue. 
Tissue biopsy should not be conducted only to perform the KRAS 
gene test unless there is neither primary cancer tissue nor met-
astatic cancer tissue.
There are many methods that can be used for KRAS gene test, 
and each method has its pros and cons. For this reason, no spe-
cific testing method is recommended for KRAS mutation testing. 
Direct sequence testing can detect all mutations existing in the 
tested area. This method has high specificity but low sensitivity 
(sensitivity of about 10–25%), so a large quantity of DNA con-
taining the mutation (at least 50% of tumor cells) is needed. Py-
rosequencing can detect cancer, if 5–10% of the entire DNA 
has the mutation. Real-time quantitative PCR can detect only 
specific target mutations, and the sensitivity is 1–10% depend-
ing on the technology (TaqMan or Scorpions ARMS, etc.). When 
PCR is combined with mutant enrichment technology, the sen-
sitivity can be improved to 0.1% or less [28]. 
If a mutation is detected, the tumor is classified as unrespon-
sive to cetuximab and panitumumab; if no mutation is detected, 
it is classified as responsive to cetuximab and panitumumab [27]. 
CONCLUSION
We suggest clinical practice guidelines for the clinical applica-
tion, interpretation, and reporting of clinically useful pharmaco-
genetics tests.
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